Despite the fact that no drug developed using artificial intelligence technology has yet gained regulatory approval for market launch, investors continue to pour fresh capital into the AI-driven drug discovery field.
Specialized venture capital firm Dimension Capital recently closed a sector-specific fund for the biotech industry that ranks among the largest of its kind.
This firm, headquartered in San Francisco and New York, completed the fundraising for its third fund, sized at $800 million, betting on the computational biology sector.
Companies in this field use 人工智能 as a core tool for developing new drugs, moving away from traditional laboratory-based methods.
The closing of this fund highlights investors' sustained enthusiasm for this niche sector: venture capital funding in this area reached $2.2 billion in 2025, a significant increase from the $599 million recorded two years prior.
Dimension Capital is already one of the most active investors in computational biology.
From 2024 through the first half of 2026, the firm's number of early-stage investments in this sector surpassed those of well-known venture capital firms like Khosla Ventures and General Catalyst.
The new fund's individual investment sizes range from under $10 million to a maximum of $100 million.
Co-founder of the fund, Zavan Dar, stated that many major competing venture capital firms are exiting software sector investments due to market fears of a potential "SaaS crash," referring to widespread sell-offs in software-as-a-service company stocks, which are seen as highly vulnerable to 人工智能 disruption.
Dar said, "Against the backdrop of pressure on SaaS companies, talent is beginning to flow into machine learning and 人工智能 fields. What was a niche industry five or six years ago is now attracting the world's top talent. As the talent flow shifts, capital is also switching tracks."
Amid this large-scale capital influx, major pharmaceutical companies like Eli Lilly and AstraZeneca have already partnered with multiple 人工智能 firms to leverage artificial intelligence for screening new drug candidates.
Data from UBS shows that globally, approximately 850 drugs discovered using 人工智能 are currently in the development pipeline, but not a single one has yet passed the U.S. regulatory approval process.
This sector is also attracting more traditional technology investors.
In January of this year, Andreessen Horowitz established a $700 million sector-specific fund to invest in companies applying 人工智能 to biotechnology and healthcare.
Jonathan Norris, Managing Director at HSBC, said, "The high market enthusiasm for investment also creates more opportunities for other incoming investors."
He also noted that increased competition might make it harder for specialized investment firms to access high-quality projects, but firms like Dimension Capital have already established themselves as leading investors in computational biology.
Dimension Capital's investment portfolio includes the Sino-American joint venture biotech firm Elandil Laboratories, which uses 人工智能 to develop immunology and oncology drugs.
The company completed an $787 million financing round in March of this year, marking the largest fundraising by a biotech firm in Europe and the U.S. this year.
The firm also invested in Coefficient Bio, which was acquired by Ansofa in April, and in Chai Drug Discovery, whose investors include OpenAI.
Dimension Capital has also invested in the gene reprogramming startup New Limit, co-founded by Coinbase CEO Brian Armstrong.
Norris commented that Dimension Capital's investment strategy is now attracting a large number of followers, but the fact that multiple companies within the firm's portfolio have successfully completed follow-on financing rounds "fills the market with confidence."
Comments